Skip to main content
UniHealth

Doctor search

Nicholas A Butowski, MD

Neurology · San Francisco

NPI 1184681009

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Office
1
Since medical school
27 years
University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1999

Offices

1 location · UCSF Medical Group Business Services · 1,533 clinicians in this group

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Butowski’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A74692 · Current

Licensed to practise in California · since 2001 · expires 2028-09-30 · University of Illinois College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Psychiatry and Neurology - Neurology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$47,633

Medicare paid this office $47,633 for 82 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)73$24,495$124
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or73$6,295$27
Advance care planning, first 30 minutes32$4,319$66
Initial hospital care with moderate level of medical decision making at least 75 minutes20$3,516$153
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's73$2,783$15
See all 7 services
Every Original Medicare service billed
Long return visit (40+ min)73$24,495$124
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or73$6,295$27
Advance care planning, first 30 minutes32$4,319$66
Initial hospital care with moderate level of medical decision making at least 75 minutes20$3,516$153
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's73$2,783$15
Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th24$2,538$27
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes11$1,996$105

Who their Medicare patients are

82 Original Medicare patients in 2024. Average age 66 · Under 65 28% · Women 46% · Also on Medicaid 26% · Health risk score 1.42. At or below the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 50% · Depression 24% · Stroke 20% · Diabetes 17% · Cancer 15%.

The office billed $296,703, Medicare allowed $61,244 and paid $47,633; for 836 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202482836661.42$296,703$47,633
202372381681.31$207,297$29,151
202270187661.13$130,764$19,607
202150126661.37$81,593$14,062
202047127621.50$89,351$11,830
20194196631.44$73,902$9,539
20184893610.95$68,175$8,922
20174289601.39$60,557$8,273
201656137591.51$93,297$12,593
201562124611.42$82,434$11,930
201459114591.18$68,293$9,480
201356108591.19$56,748$7,807

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Long return visit (40+ min)59$19,730$119
Initial hospital care with moderate level of medical decision making at least 75 minutes15$2,335$156
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or36$1,822$27
Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th14$797$27

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)57$14,524$115
New patient visit (60+ min)12$1,950$162
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or17$537$27

2021: 1 service

Original Medicare services billed in 2021
Long return visit (40+ min)34$9,836$129

2020: 1 service

Original Medicare services billed in 2020
Long return visit (40+ min)35$7,659$93

2019: 1 service

Original Medicare services billed in 2019
Long return visit (40+ min)35$6,523$91

2018: 1 service

Original Medicare services billed in 2018
Long return visit (40+ min)42$7,442$92

2017: 1 service

Original Medicare services billed in 2017
Long return visit (40+ min)35$6,905$92

2016: 2 services

Original Medicare services billed in 2016
Long return visit (40+ min)48$10,055$92
Return visit (30+ min)12$945$59

2015: 2 services

Original Medicare services billed in 2015
Long return visit (40+ min)33$7,338$98
Return visit (30+ min)20$1,965$65

2014: 2 services

Original Medicare services billed in 2014
Long return visit (40+ min)20$4,011$93
Return visit (30+ min)26$3,010$61

2013: 2 services

Original Medicare services billed in 2013
Long return visit (40+ min)24$3,900$85
Return visit (30+ min)26$2,013$59

Medicaid work

$7,941 in 2024

Medicaid paid $7,941 for 67 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)67$7,941
Medicaid work by year
202467115$7,941
202213113$1,344
See the largest Medicaid services in earlier years

2022

Largest Medicaid services in 2022
Long return visit (40+ min)13$1,344

Drugs they prescribed that Part D paid

$35,958

Pharmacies billed $35,958 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 89) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.

83 generic and fewer than 11 brand-name prescriptions · $35,958 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Levetiracetam17$845$50
Dexamethasone12$200$17

Year by year

Part D prescribing by year
202489250% (0)None$35,958
202394230% (0)None$7,475
202287210% (0)None$5,552
20219119None16%$13,492
202095210% (0)15%$14,468
2019112240% (0)None$24,148
2018114210% (0)None$3,555
201794190% (0)None$4,193
2016150260% (0)None$6,955
201591180% (0)None$4,438
201481160% (0)None$5,385
201386160% (0)15%$6,053

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 5 drugs

Part D drugs prescribed in 2023
Levetiracetam30$2,663$89
Dexamethasone11$168$15
Ondansetron11$148$13
Lamotrigine12$142$12
Lisinopril-Hydrochlorothiazide12$67$6

2022: 2 drugs

Part D drugs prescribed in 2022
Levetiracetam34$2,096$62
Dexamethasone12$433$36

2021: 2 drugs

Part D drugs prescribed in 2021
Levetiracetam33$2,029$61
Pregabalin13$169$13

2020: 3 drugs

Part D drugs prescribed in 2020
Gleostine11$9,298$845
Levetiracetam36$1,317$37
Gabapentin12$69$6

2019: 3 drugs

Part D drugs prescribed in 2019
Levetiracetam47$1,249$27
Lamotrigine12$240$20
Gabapentin14$65$5

2018: 1 drug

Part D drugs prescribed in 2018
Levetiracetam57$1,549$27

2017: 1 drug

Part D drugs prescribed in 2017
Levetiracetam53$1,607$30

2016: 4 drugs

Part D drugs prescribed in 2016
Levetiracetam67$1,529$23
Carbamazepine11$685$62
Dexamethasone14$411$29
Lamotrigine21$141$7

2015: 1 drug

Part D drugs prescribed in 2015
Levetiracetam57$1,021$18

2014: 3 drugs

Part D drugs prescribed in 2014
Levetiracetam32$827$26
Phenytoin Sodium Extended11$478$43
Dexamethasone13$257$20

2013: 3 drugs

Part D drugs prescribed in 2013
Levetiracetam26$1,339$51
Phenytoin Sodium Extended12$284$24
Ondansetron14$252$18

Money from drug and device companies

$2,730 in 2025

Industry payments by year
202512$2,730$2,730
202423$2,610$2,655
202344$5,931$5,973
202222$2,321$2,321
202113$3,879$3,879
202011None$67
2019410$6,213$6,656

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Ipsen BiopharmaceuticalsNone$2,730
2 payments
  • Consulting · 2025-07-09 · $1,365
  • Consulting · 2025-06-09 · $1,365
See all 2 published payments
Every published payment
Ipsen BiopharmaceuticalsConsulting · 2025-07-09None$1,365
Ipsen BiopharmaceuticalsConsulting · 2025-06-09None$1,365
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $2,655

Payments by company in 2024
Ipsen BiopharmaceuticalsNone$2,610
2 payments
  • Consulting · 2024-08-23 · $1,305
  • Consulting · 2024-06-28 · $1,305
Boston ScientificTherasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial)$45
1 payment
  • Meals for Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) · 2024-11-22 · $45

2023: $5,973

Payments by company in 2023
Servier PharmaceuticalsNone$4,080
1 payment
  • Consulting · 2023-09-27 · $4,080
Bayer Healthcare PharmaceuticalsVitrakvi$1,199
1 payment
  • Consulting for Vitrakvi · 2023-09-14 · $1,199
Ipsen BiopharmaceuticalsNone$653
1 payment
  • Consulting · 2023-11-24 · $653
Boston ScientificNone$42
1 payment
  • Meals · 2023-11-16 · $42

2022: $2,321

Payments by company in 2022
Stemline TherapeuticsNone$1,920
1 payment
  • Consulting · 2022-09-28 · $1,920
Ipsen BiopharmaceuticalsNone$401
1 payment
  • Consulting · 2022-01-01 · $401

2021: $3,879

Payments by company in 2021
Ipsen BiopharmaceuticalsNone$3,879
3 payments
  • Consulting · 2021-07-09 · $2,140
  • Consulting · 2021-04-15 · $401
  • Consulting · 2021-02-05 · $1,338

2020: $67

Payments by company in 2020
AmgenNone$67
1 payment
  • Meals · 2020-01-27 · $67

2019: $6,656

Payments by company in 2019
AmgenNone$3,546
6 payments
  • Consulting · 2019-12-10 · $2,750
  • Meals · 2019-11-19 · $60
  • Meals · 2019-11-19 · $12
  • Travel · 2019-11-18 · $144
  • Travel · 2019-11-18 · $169
  • Consulting · 2019-09-13 · $413
Bayer HealthCare PharmaceuticalsStivarga$2,510
2 payments
  • Consulting for Stivarga · 2019-07-15 · $2,450
  • Meals for Stivarga · 2019-05-30 · $60
Jazz PharmaceuticalsNone$550
1 payment
  • Consulting · 2019-01-17 · $550
Ipsen BiopharmaceuticalsNone$50
1 payment
  • Consulting · 2019-11-04 · $50

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2020Their institution$418,142
Boston Scientific Corporation · Frontier · 2024Their institution$365,330
Boston Scientific Corporation · Frontier · 2025Their institution$312,237
Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery Ofliposomal-Irinotecan Using Real-Time Imaging With Gadoliniumin Patients With Recurrent High Grade Glioma · 2019Their institution$178,828
AbbVie, Inc. · 2019Their institution$151,204
Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2022Their institution$117,728
Sumitomo Pharma America, Inc. · A Phase 1 Study of Dsp-0390 in Patients With Recurrent High-Grade Glioma · 2024Their institution$70,719
E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2020Their institution$67,561
Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2023Their institution$59,125
Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2024Their institution$49,364
Bayer HealthCare Pharmaceuticals Inc. · Stivarga · 2021Their institution$45,610
Bayer HealthCare Pharmaceuticals Inc. · Global Ma Regorafenib Pre-Clinical Rego and Nivo in Gbm Vineta · 2022Their institution$45,610
AstraZeneca UK Limited · A Modular Phase I/Iia, Open-Label, Multi-Centre Study To Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of Azd9574 As Monotherapy and in Combination With Anti-Cancer Agents in Patients With Advanced Solid Malignancies (Certis1) · 2023Their institution$34,686
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2022Their institution$32,913
Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2021Their institution$32,614
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt (Nivo Mono Rt) - A Randomized Phase 3 Open Label Study of Nivolumab Vs Temozolo Mide Each in Combination With Radiat Ion Therapy in Newly Diagnosed Adult Subjects With Unmethylated Mgmt (Tumor O-6 Methylguanine Dna Meth · 2023Their institution$31,094
Boston Scientific Corporation · Frontier · 2023Their institution$29,812
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2021Their institution$28,084
E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l (Registrational) - A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and A Safety Study of Nivolumab Or Nivolumab in Combination With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (Gbm) · 2023Their institution$26,641
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2024Their institution$24,911
AstraZeneca UK Limited · A Modular Phase I/Iia, Open-Label, Multi-Centre Study To Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of Azd9574 As Monotherapy and in Combination With Anti-Cancer Agents in Patients With Advanced Solid Malignancies (Certis1) · 2024Their institution$24,609
Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecanusing Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2021Their institution$22,828
Sumitomo Pharma America, Inc. · A Phase 1 Study of Dsp-0390 in Patients With Recurrent High-Grade Glioma · 2025Their institution$22,455
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2022Their institution$21,852
JAZZ PHARMACEUTICALS INC. · Onc201 for the Treatment of Newly Diagnosed H3 K27m-Mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study · 2025Their institution$20,921
BeiGene, Ltd. · A Phase 1b/2 Study To Assess the Safety, Tolerability and Efficacy of Bgb-290 in Combination With Radiation Therapy (Rt) and/Or Temozolomide (Tmz) in Subjects With First-Line Or Recurrent/Refractory Glioblastoma · 2020Their institution$19,538
Kadmon Corporation LLC · A Phase 2 Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma · 2019Their institution$18,446
AstraZeneca UK Limited · A Modular Phase I/Iia, Open-Label, Multi-Centre Study To Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of Azd9574 As Monotherapy and in Combination With Anti-Cancer Agents in Patients With Advanced Solid Malignancies (Certis1) · 2025Their institution$17,503
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2022Their institution$14,570
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2021Their institution$13,965
Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2019Their institution$10,556
ABBVIE INC. · A Study of Abt-414 in Participants With Newly Diagnosed Glioblastoma (Gbm) With Epidermal Growth Factor Receptor (Egfr) Amplification · 2023Their institution$9,724
ABBVIE INC. · A Randomized, Placebo Controlled Phase 3 Study of Abt-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (Gbm) With Epidermal Growth Factor Receptor (Egfr) Amplification (Intellance1) · 2021Their institution$9,518
E.R. Squibb & Sons, L.L.C. · Ph III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2022Their institution$9,230
Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2022Their institution$7,821
AbbVie Inc. · 2020Their institution$7,046
BeiGene, Ltd. · A Phase 1b/2 Study To Assess the Safety, Tolerability and Efficacy of Bgb-290 in Combination With Radiation Therapy (Rt) and/Or Temozolomide (Tmz) in Subjects With First-Line Or Recurrent/Refractory Glioblastoma · 2021Their institution$6,437
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2023Their institution$5,985
Arbor Pharmaceuticals, Inc. · Vigilant Observation of Gliadel Wafer Implant Registry (Vigilant) · 2020This clinician$5,768
E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2019Their institution$5,232
Arbor Pharmaceuticals, Inc. · Vigilant Observation of Gliadel Wafer Implant Registry Vigilant · 2019This clinician$3,591
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2020Their institution$1,875
E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l (Registrational) - A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and A Safety Study of Nivolumab Or Nivolumab in Combination With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (Gbm) · 2024Their institution$1,163
E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2021Their institution$625
Sumitomo Pharma America, Inc. · A Phase 1 Study of Dsp-0390 in Patients With Recurrent High-Grade Glioma · 2023Their institution$396

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1184681009
Licence
CA A74692California A74692: Current · expires 2028-09-30
Trained
University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1999 · 27 years ago
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00A746920
Taxonomy
Federal specialty code 207T00000X (207T00000X)
Mailing address
1635 Divisadero St, Ste 625, Box 1821, San Francisco, CA, 94143
NPI first listed
2006-04-26
NPI last updated
2008-07-23

This is when the NPI record was last certified, not a medical board exam.